Collagen-induced arthritis in nonhuman primates: multiple epitopes of type II collagen can induce autoimmune-mediated arthritis in outbred cynomolgus monkeys.
OBJECTIVE
To define which regions of the type II collagen (CII) molecule result in anticollagen antibody production and the subsequent development of autoantibodies in a collagen-induced arthritis (CIA) nonhuman primate model.


METHODS
Male and female cynomolgus monkeys (2-6 of each sex per group) were immunized with either chicken (Ch), human, or monkey (Mk) CII, or with cyanogen bromide (CB)-generated peptide fragments of ChCII emulsified in Freund's complete adjuvant. Monkeys were observed for the development of arthritis, and sera were collected and analyzed for anticollagen antibody specificity by enzyme-linked immunosorbent assay.


RESULTS
Overt arthritis developed in all groups of monkeys immunized with intact CII and with all major CB peptide fragments of ChCII except CB8. Onset and severity of arthritis correlated best with serum anti-MkCII antibody levels. The levels of IgG autoantibody to MkCII were a result of the cross-reactivity rate of anti-heterologous CII antibodies with MkCII, which was based on the genetic background of individual monkeys rather than on sex differences.


CONCLUSIONS
CII from several species and disparate regions of the CII molecule were able to induce autoantibody-mediated arthritis in outbred cynomolgus monkeys. The strong anti-MkCII response suggests that epitope spreading or induction of broad-based CII cross-reactivity occurred in these animals. Autoantibody levels to MkCII were higher in CIA-susceptible monkeys than in resistant monkeys, despite comparable antibody levels in response to the various immunizations of CII. These results closely parallel the type of anticollagen responses found in sera from rheumatoid arthritis patients. Perhaps this can be accounted for by similar major histocompatibility complex heterogenicity associated with an outbred population, or maybe this is a primate-specific pattern of reactivity to CII.
Shimozuru
Y
Y
Eisai Company Ltd., Tsukuba Research Laboratories, Japan.
Yamane
S
S
Fujimoto
K
K
Terao
K
K
Honjo
S
S
Nagai
Y
Y
Sawitzke
A D
AD
Terato
K
K
D000818:Animals; D001168:Arthritis / Q000000981:diagnostic imaging / Q000276:immunology*; D001175:Arthrography; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology*; D002645:Chickens; D003094:Collagen / Q000737:chemistry / Q000187:drug effects / Q000276:immunology*; D003488:Cyanogen Bromide / Q000494:pharmacology; D000939:Epitopes / Q000276:immunology*; D005260:Female; D006801:Humans; D007114:Immunization; D008252:Macaca fascicularis / Q000276:immunology*; D008297:Male; D010446:Peptide Fragments / Q000276:immunology
D001323:Autoantibodies; D000939:Epitopes; D010446:Peptide Fragments; D003094:Collagen; D003488:Cyanogen Bromide